Aimee Tharaldson, PharmD, Discusses the Biosimilar Pathway

Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway and compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy's Educational Conference.

Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy’s Educational Conference. Once more guidance is available from the FDA, there will be more biosimilar approvals, Dr. Tharaldson told the American Journal of Managed Care.